238 related articles for article (PubMed ID: 28819040)
1. Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities.
Kaufman TM; Duell PB; Purnell JQ; Wójcik C; Fazio S; Shapiro MD
Circ Res; 2017 Aug; 121(5):499-501. PubMed ID: 28819040
[No Abstract] [Full Text] [Related]
2. [In process].
Reisdorf S
Med Monatsschr Pharm; 2017 Jun; 40(6):271-3. PubMed ID: 29979855
[No Abstract] [Full Text] [Related]
3. JAMA PATIENT PAGE. PCSK9 Inhibitors for Treating High Cholesterol.
Jin J
JAMA; 2015 Dec; 314(21):2320. PubMed ID: 26624842
[No Abstract] [Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
5. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
Wang Y; Liu ZP
Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
Blom DJ; Dent R; Castro RC; Toth PP
Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
[TBL] [Abstract][Full Text] [Related]
7. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
Sible AM; Nawarskas JJ; Anderson JR
Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
[TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
11. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
Stein EA
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553
[TBL] [Abstract][Full Text] [Related]
12. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].
Lettino M
G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756
[No Abstract] [Full Text] [Related]
13. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.
Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A
Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061
[TBL] [Abstract][Full Text] [Related]
14. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
[TBL] [Abstract][Full Text] [Related]
15. Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol.
Seidah NG
Nat Struct Mol Biol; 2017 Oct; 24(10):785-786. PubMed ID: 28981076
[No Abstract] [Full Text] [Related]
16. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.
Lambert G; Thedrez A; Croyal M; Ramin-Mangata S; Couret D; Diotel N; Nobécourt-Dupuy E; Krempf M; LeBail JC; Poirier B; Blankenstein J; Villard EF; Guillot E
Clin Sci (Lond); 2017 Feb; 131(4):261-268. PubMed ID: 28108631
[TBL] [Abstract][Full Text] [Related]
17. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
18. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
Guijarro C; Ruilope LM
Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
[No Abstract] [Full Text] [Related]
19. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
[No Abstract] [Full Text] [Related]
20. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine.
Uppugunduri CR; George M
J Cardiovasc Pharmacol; 2016 Feb; 67(2):191-2. PubMed ID: 26398165
[No Abstract] [Full Text] [Related]
[Next] [New Search]
